PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $21.00 target price on the stock.

Several other research firms have also issued reports on PDSB. Cantor Fitzgerald restated an overweight rating on shares of PDS Biotechnology in a research report on Friday, January 12th. StockNews.com cut PDS Biotechnology from a hold rating to a sell rating in a research report on Saturday, March 16th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $17.67.

PDS Biotechnology Price Performance

Shares of NASDAQ:PDSB opened at $3.85 on Wednesday. The company has a market cap of $119.77 million, a price-to-earnings ratio of -2.25 and a beta of 1.72. The business has a 50 day moving average price of $5.26 and a 200 day moving average price of $5.11. The company has a quick ratio of 6.21, a current ratio of 6.21 and a debt-to-equity ratio of 0.96. PDS Biotechnology has a twelve month low of $3.61 and a twelve month high of $10.27.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PDSB. BlackRock Inc. increased its position in shares of PDS Biotechnology by 276.6% during the 2nd quarter. BlackRock Inc. now owns 1,732,918 shares of the company’s stock worth $8,717,000 after purchasing an additional 1,272,801 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of PDS Biotechnology by 5.0% during the third quarter. Vanguard Group Inc. now owns 1,148,078 shares of the company’s stock worth $3,410,000 after purchasing an additional 54,193 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of PDS Biotechnology by 49.5% in the first quarter. Renaissance Technologies LLC now owns 665,037 shares of the company’s stock valued at $4,117,000 after buying an additional 220,300 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of PDS Biotechnology by 18.6% in the first quarter. Two Sigma Investments LP now owns 589,050 shares of the company’s stock valued at $3,623,000 after buying an additional 92,581 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its position in PDS Biotechnology by 4.5% during the 1st quarter. Two Sigma Advisers LP now owns 584,400 shares of the company’s stock worth $3,594,000 after buying an additional 25,200 shares in the last quarter. 26.84% of the stock is owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.